selected publications
-
article
-
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
Arthritis %26 rheumatology (Hoboken, N.J.).
67:2759-2770.
2015-01-01
-
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Arthritis and Rheumatism.
62:1792-1802.
2010-01-01
-
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
The Lancet.
372:383-391.
2008-01-01
-
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
Arthritis %26 rheumatology (Hoboken, N.J.).
67:2759-2770.
2015-01-01